Perrigo (NYSE:PRGO) has been given a $105.00 price objective by research analysts at Canaccord Genuity in a note issued to investors on Monday. The brokerage presently has a “buy” rating on the stock. Canaccord Genuity’s price target would suggest a potential upside of 40.11% from the company’s previous close.
PRGO has been the topic of several other reports. Cantor Fitzgerald set a $107.00 price target on Perrigo and gave the stock a “buy” rating in a research report on Monday. Oppenheimer set a $98.00 price target on Perrigo and gave the stock a “buy” rating in a research report on Friday. ValuEngine downgraded Perrigo from a “hold” rating to a “sell” rating in a research report on Wednesday, May 9th. Wells Fargo set a $84.00 price target on Perrigo and gave the stock a “market perform” rating in a research report on Monday. Finally, Berenberg Bank initiated coverage on Perrigo in a research report on Thursday, February 1st. They set a “buy” rating and a $117.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, eight have given a hold rating and nine have given a buy rating to the company’s stock. Perrigo has an average rating of “Hold” and an average price target of $93.06.
NYSE PRGO opened at $74.94 on Monday. The company has a debt-to-equity ratio of 0.53, a quick ratio of 1.48 and a current ratio of 2.08. Perrigo has a 1 year low of $71.37 and a 1 year high of $75.36. The firm has a market capitalization of $10.73 billion, a P/E ratio of 15.20, a PEG ratio of 1.91 and a beta of 0.77.
Perrigo (NYSE:PRGO) last released its earnings results on Tuesday, May 8th. The company reported $1.26 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.14 by $0.12. Perrigo had a return on equity of 11.93% and a net margin of 2.59%. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.21 billion. During the same period in the prior year, the firm earned $1.05 EPS. The firm’s revenue was up 1.9% on a year-over-year basis. analysts expect that Perrigo will post 5.27 earnings per share for the current fiscal year.
In other news, CEO Uwe Roehrhoff bought 7,500 shares of the stock in a transaction dated Monday, March 5th. The shares were acquired at an average cost of $81.85 per share, with a total value of $613,875.00. Following the purchase, the chief executive officer now directly owns 4,900 shares in the company, valued at approximately $401,065. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Corporate insiders own 6.90% of the company’s stock.
Several hedge funds have recently bought and sold shares of the company. Allianz Asset Management GmbH purchased a new stake in shares of Perrigo during the 1st quarter worth about $205,000. Rampart Investment Management Company LLC lifted its stake in Perrigo by 112.0% in the 1st quarter. Rampart Investment Management Company LLC now owns 3,498 shares of the company’s stock valued at $292,000 after buying an additional 1,848 shares in the last quarter. Clinton Group Inc. purchased a new position in Perrigo in the 1st quarter valued at about $222,000. Credit Agricole S A lifted its stake in Perrigo by 18.8% in the 1st quarter. Credit Agricole S A now owns 65,373 shares of the company’s stock valued at $5,447,000 after buying an additional 10,350 shares in the last quarter. Finally, Cooke & Bieler LP lifted its stake in Perrigo by 1.2% in the 1st quarter. Cooke & Bieler LP now owns 85,123 shares of the company’s stock valued at $7,094,000 after buying an additional 1,000 shares in the last quarter. 79.52% of the stock is currently owned by institutional investors and hedge funds.
Perrigo Company plc, a healthcare company, manufactures and supplies over-the-counter (OTC) healthcare products, infant formulas, branded OTC products, and generic pharmaceutical products worldwide. The company operates through Consumer Healthcare Americas, Consumer Healthcare International, and Prescription Pharmaceuticals segments.
Receive News & Ratings for Perrigo Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Perrigo and related companies with MarketBeat.com's FREE daily email newsletter.